trending Market Intelligence /marketintelligence/en/news-insights/trending/6Zld97fHj3I_nQU27xNisw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bellicum CAR-T therapy shows promise in phase 1/2 pancreatic cancer study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bellicum CAR-T therapy shows promise in phase 1/2 pancreatic cancer study

SNL Image

Bellicum Pharmaceuticals Inc. said its cell therapy BPX-601 showed promise in an early-stage study in patients with advanced pancreatic cancer.

The 12-patient phase 1/2 trial enrolled subjects with advanced pancreatic cancer which has spread across the body and whose disease express a protein called prostate stem cell antigen.

BPX-601 is a chimeric antigen receptor T cell, or CAR-T, therapy, which involves taking a person's own immune cells and modifying them to fight cancer cells when infused back into the body. The effects of Bellicum's therapy are designed to be boosted by administering a drug called rimiducid, which acts as an activation switch for the treatment.

Patients treated with BPX-601 but were not given rimiducid showed limited expansion in the CAR-T cells and the cells did not persist.

Meanwhile, four patients given a single dose of rimiducid seven days after being treated with BPX-601 showed a significant expansion of CAR-T cells, with the expansion ranging from 3x to 20x. The CAR-T cells also persisted by over three weeks in three patients who were also given rimiducid.

Further, four out of six evaluable patients treated with BPX-601 and given a single dose of rimiducid achieved stable disease — no new tumors appear and known cancers neither shrink or grow — while two patients saw their tumors shrink by over 20%.

Side effects of the therapy were consistent with those commonly observed in advanced cancer patients undergoing cytotoxic chemotherapy or other cancer immunotherapies.

Houston-based Bellicum plans to study BPX-601 further in patients with prostate and gastric cancers, with additional doses of rimiducid and along with a more complete conditioning regimen. CEO Rick Fair said the company plans to report updated results for the therapy in 2019.